Markeri značajni za prognozu i terapiju tumora pasa

Abstract

Višestruki onkogeni efekti utiču na inhibiciju maturacije ćelije, migraciju i tkivnu invaziju. Razvoj tumora podrazumeva nesklad između proliferacije, rasta i diferencijacije, što je praćeno značajnim genotipskim i fenotipskim varijacijama. Kvalitativno i kvantitativno određivanje bioloških prognostičkih faktora u tkivu govori o metastatskom potencijalu tumora i predikciji neoplastične bolesti. Faktore angiogeneze i brojne aktivirajuće i inhibitorne proteine moguće je imunohistohemijski dokazati u tkivu tumora, a imunofenotipizacija limfoma je nužna za izbor terapijskog protokola. Određivanje proliferativnog potencijala tumorskih ćelija imunohistohemijskom detekcijom PCNA, Ki-67, CD-117, CD45 koristi se u gradiranju mastocitoma. Sve je značajnija klinička korelacija rasta tumora sa ekspresijom različitih antigena na tumorskim ćelijama.

The multiple oncogenic effects on the inhibition of cell maturation, on cell migration and tissue invasion, is responsible for the occurrence of tumours. The development of tumours implies a disproportion between proliferation, growth and differentiation, which is accompanied by significant genotypic and phenotypic variations in the diseased. The qualitative and quantitative determination of the biological prognostic factors in the tissue indicates possible tumour metastasizing, and consequently also the prognosis of the neoplastic disease. It is possible immunohistochemically to prove factors of angiogenesis and numerous activating and inhibiting proteins in the tumour tissue, which is also very important for properly choice of lymphoma therapy. The determination of the proliferative potential of tumour cells by immunohistochemical detection of PCNA, Ki-67, CD-117, CD 45, is used in grading of mast cell tumours. In addition to other histological, clinical and biological parameters, they are significant for the further prognosis and therapy of neoplasms.